Zarxio Coverage On Par With Innovators Even Without Interchangeable Designation
Executive Summary
Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.
You may also be interested in...
Spectrum Gears Up To File Rolontis, Stresses Patient Access
Biosimilars of Amgen's blockbuster Neulasta pose a competitive threat to long-acting GSF Rolontis, but the company has experience with group purchasing and notes that large oncology clinics will make more revenue by providing higher-priced products.
US Generic Drug Spending Declines In A New Development – IQVIA Report
Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.
US Generic Drug Spending Declines In A New Development – IQVIA Report
Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.